Publications (39)

2021

  1. NMDA receptor–BK channel coupling regulates synaptic plasticity in the barrel cortex

    Proceedings of the National Academy of Sciences, Vol. 118, Núm. 35, pp. e2107026118

2014

  1. Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents

    Cardiovascular Research, Vol. 104, Núm. 2, pp. 337-346

2010

  1. Cardiac electrophysiological effects of nitric oxide

    Cardiovascular Research, Vol. 87, Núm. 4, pp. 593-600

  2. In Humans, Chronic Atrial Fibrillation Decreases the Transient Outward Current and Ultrarapid Component of the Delayed Rectifier Current Differentially on Each Atria and Increases the Slow Component of the Delayed Rectifier Current in Both

    Journal of the American College of Cardiology, Vol. 55, Núm. 21, pp. 2346-2354

  3. Flecainide increases Kir2.1 currents by interacting with cysteine 311, decreasing the polyamine-induced rectification

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Núm. 35, pp. 15631-15636

  4. Farmacología clínica de la ranolazina, un nuevo fármaco en el tratamiento de la angina crónica estable

    Revista Espanola de Cardiologia Suplementos, Vol. 10, Núm. 2, pp. 41-54

  5. Farmacología clínica de la ranolazina, un nuevo fármaco en el tratamiento de la angina crónica estable

    Revista Espanola de Cardiologia Suplementos, Vol. 10, Núm. 1

  6. Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner

    Journal of Molecular and Cellular Cardiology, Vol. 48, Núm. 1, pp. 201-210

  7. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner

    Cardiovascular Research, Vol. 85, Núm. 1, pp. 56-67

  8. Clinical Pharmacology of Ranolazine, a Novel Compound for Treating Chronic Stable Angina

    Revista Espanola de Cardiologia Suplementos, Vol. 10, Núm. SUPPL. 2

2009

  1. IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation

    Expert Opinion on Investigational Drugs, Vol. 18, Núm. 4, pp. 399-416